DIPYRIDAMOLE Drug Interactions
Also known as: Dipyridamole
Dipyridamole is a medication that helps prevent blood clots. It works by making platelets, tiny blood cells involved in clotting, less sticky. This medicine is primarily used alongside other blood thinners to prevent dangerous blood clots after heart valve replacement surgery.DIPYRIDAMOLE has 10 documented drug interactions in our database, including 0 contraindicated, 10 major, 0 moderate, and 0 minor interactions.
0
Contraindicated
10
Major
0
Moderate
0
Minor
Combining naproxen with dipyridamole significantly increases your risk of bleeding, especially in the stomach or intestines. You should avoid taking these medications together unless specifically instructed by your doctor.
Mechanism
Naproxen, an NSAID, inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis and impairing platelet aggregation. Dipyridamole is an antiplatelet agent that also inhibits platelet function. The co-administration of these two drugs leads to an additive antiplatelet effect, significantly increasing the risk of bleeding.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding, which can manifest as stomach pain, black or bloody stools, or vomiting blood. Other bleeding risks include bruising, nosebleeds, and prolonged bleeding from cuts. The risk of serious GI bleeding can be several-fold higher compared to either drug alone. Concomitant use of naproxen and dipyridamole should generally be avoided due to the high bleeding risk. If anti-inflammatory or analgesic therapy is required, consider alternative pain relief options such as acetaminophen. If antiplatelet therapy is essential, re-evaluate the need for naproxen or consider a gastroprotective agent if co-administration is unavoidable and closely monitor for signs of bleeding.
Combining etodolac with dipyridamole significantly increases your risk of bleeding, especially in the stomach or intestines. This combination should generally be avoided.
Mechanism
Etodolac, an NSAID, inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and impairing platelet aggregation. Dipyridamole also inhibits platelet aggregation by increasing cyclic AMP levels in platelets and inhibiting phosphodiesterase. The concurrent use of these agents results in additive antiplatelet effects.
Clinical Management
This interaction leads to a substantially increased risk of bleeding, particularly gastrointestinal bleeding, which can range from minor ecchymoses to severe, life-threatening hemorrhage. The risk of major gastrointestinal bleeding with NSAID use alone is increased by 3-5 times, and concurrent antiplatelet agents further amplify this risk. This combination should generally be avoided due to the high bleeding risk. If concurrent use is absolutely necessary, monitor closely for signs of bleeding (e.g., black stools, easy bruising, nosebleeds) and consider gastroprotective agents (e.g., proton pump inhibitors). Evaluate alternative pain management strategies or antiplatelet therapies if possible.
Combining aspirin and dipyridamole significantly increases your risk of bleeding, including serious stomach or intestinal bleeding, due to their combined effects on blood clotting.
Mechanism
Both aspirin and dipyridamole inhibit platelet aggregation, albeit through different mechanisms. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1), preventing thromboxane A2 production, while dipyridamole inhibits phosphodiesterase, increasing cyclic AMP and reducing platelet adhesion. Their additive antiplatelet effects lead to a heightened risk of hemorrhage.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding. This includes gastrointestinal bleeding (e.g., peptic ulcer, melena, hematemesis), intracranial hemorrhage, epistaxis, and bruising. The risk of major bleeding is significantly elevated compared to monotherapy, potentially increasing 2-3 fold. This combination should generally be avoided unless the benefits clearly outweigh the risks and under close medical supervision. If co-administration is deemed necessary, monitor patients closely for signs of bleeding, such as black stools, unusual bruising, or prolonged bleeding from cuts. Consider proton pump inhibitor co-therapy to mitigate GI bleeding risk, and use the lowest effective doses of both medications.
Combining ibuprofen with dipyridamole significantly increases your risk of bleeding, especially from the stomach or intestines. This combination should generally be avoided.
Mechanism
Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and impairing platelet aggregation. Dipyridamole is an antiplatelet agent that inhibits phosphodiesterase, leading to increased cyclic AMP and further impairing platelet function. The concomitant use results in additive antiplatelet effects and increased gastrointestinal mucosal damage.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, including gastrointestinal bleeding (e.g., ulcers, melena, hematemesis), intracranial hemorrhage, and other forms of hemorrhage. The risk of serious gastrointestinal bleeding with NSAID plus antiplatelet therapy can be several-fold higher compared to either agent alone. This combination should generally be avoided due to the high bleeding risk. If concurrent use is unavoidable, the patient should be closely monitored for signs of bleeding (e.g., black/tarry stools, unusual bruising, weakness) and the lowest effective doses for the shortest duration should be used. Consider alternative pain management strategies or antiplatelet agents if appropriate. Gastroprotective agents (e.g., proton pump inhibitors) may be considered but do not eliminate the risk.
Combining indomethacin with dipyridamole significantly increases your risk of bleeding, especially in the stomach or intestines. This combination should generally be avoided.
Mechanism
Indomethacin, an NSAID, inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and impairing platelet aggregation. Dipyridamole is an antiplatelet agent that inhibits phosphodiesterase, leading to increased cyclic AMP and reduced platelet aggregation. The concurrent use of these agents results in additive antiplatelet effects, significantly prolonging bleeding time.
Clinical Management
Patients are at a substantially increased risk of serious bleeding events, including gastrointestinal bleeding, intracranial hemorrhage, and other forms of hemorrhage. The risk of gastrointestinal bleeding with NSAIDs alone is already elevated, and antiplatelets further amplify this risk. Symptoms may include black, tarry stools, vomiting blood, or unusual bruising. This combination should generally be avoided due to the high bleeding risk. If concurrent use is absolutely necessary, patients require very close monitoring for signs of bleeding, and the lowest effective doses should be used for the shortest possible duration. Consider alternative pain management strategies or alternative antiplatelet therapies if appropriate.
Combining celecoxib with dipyridamole significantly increases your risk of bleeding, especially in the stomach or intestines. This combination should generally be avoided.
Mechanism
Celecoxib, an NSAID, inhibits prostaglandin synthesis, which can impair gastric mucosal protection and platelet function. Dipyridamole is an antiplatelet agent that inhibits phosphodiesterase, leading to increased cyclic AMP and reduced platelet aggregation. The combined antiplatelet effects and gastrointestinal mucosal damage synergistically elevate bleeding risk.
Clinical Management
Patients are at a substantially increased risk of serious bleeding events, including gastrointestinal hemorrhage, intracranial hemorrhage, and other forms of acute bleeding. The risk of major gastrointestinal bleeding can be several-fold higher compared to either drug alone, potentially leading to anemia, hypotension, or even death. This combination should generally be avoided due to the high risk of bleeding. If concurrent therapy is absolutely necessary, closely monitor for signs of bleeding (e.g., black stools, easy bruising, nosebleeds), and consider gastroprotective agents like proton pump inhibitors. Alternative pain management strategies or antiplatelet therapies with lower bleeding risk should be explored.
Combining piroxicam with dipyridamole significantly increases your risk of bleeding, especially from the stomach or intestines. This combination should generally be avoided.
Mechanism
Piroxicam, a non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and platelet aggregation. Dipyridamole is an antiplatelet agent that inhibits phosphodiesterase, leading to increased cyclic AMP and reduced platelet aggregation. The concurrent use of these agents results in additive antiplatelet effects, significantly impairing hemostasis.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, including gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and other serious bleeding events. The risk of serious GI bleeding with NSAID plus antiplatelet therapy can be several-fold higher compared to either drug alone. This combination is generally not recommended due to the high bleeding risk. If concurrent use is unavoidable, patients must be closely monitored for signs of bleeding, and a proton pump inhibitor (PPI) should be co-prescribed to reduce GI bleeding risk. Consider alternative pain management strategies or alternative antiplatelet agents if possible.
Combining meloxicam with dipyridamole significantly increases your risk of bleeding, especially in the stomach or intestines. This combination should generally be avoided.
Mechanism
Meloxicam, a non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and impairing platelet aggregation. Dipyridamole is an antiplatelet agent that inhibits phosphodiesterase, leading to increased cyclic AMP and reduced platelet aggregation. The concurrent use of these agents results in an additive antiplatelet effect, significantly increasing the risk of hemorrhage.
Clinical Management
Patients are at a substantially increased risk of serious bleeding events, including gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and other forms of systemic bleeding. The risk of major GI bleeding with NSAIDs combined with antiplatelets can be several-fold higher than with either agent alone, potentially leading to anemia, hospitalization, or life-threatening complications. This combination should generally be avoided due to the high risk of bleeding. If concurrent use is unavoidable, patients must be closely monitored for signs and symptoms of bleeding (e.g., black/tarry stools, unusual bruising, prolonged bleeding from cuts). Consider alternative pain management strategies or alternative antiplatelet agents with a lower bleeding risk, if appropriate and clinically feasible. Proton pump inhibitor prophylaxis may be considered if NSAID use is absolutely necessary.
Combining diclofenac (an NSAID) with dipyridamole (an antiplatelet) significantly increases your risk of bleeding, especially in the stomach or intestines. This combination should generally be avoided.
Mechanism
Diclofenac inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which can impair gastric mucosal protection and inhibit platelet aggregation. Dipyridamole inhibits phosphodiesterase, leading to increased cyclic AMP and reduced platelet aggregation. The combination results in additive antiplatelet effects and increased gastrointestinal toxicity.
Clinical Management
The primary clinical effect is a significantly increased risk of bleeding, including gastrointestinal bleeding (e.g., ulcers, hemorrhage), bruising, nosebleeds, and prolonged bleeding from cuts. The risk of serious GI bleeding can be several-fold higher compared to either drug alone, potentially leading to anemia or requiring hospitalization. This combination should generally be avoided due to the high bleeding risk. If concurrent use is unavoidable, patients must be closely monitored for signs of bleeding (e.g., black/tarry stools, unusual bruising, weakness). Consider alternative pain relief not affecting platelets or gastric mucosa, such as acetaminophen. If an NSAID is absolutely necessary, use the lowest effective dose for the shortest duration, and consider a proton pump inhibitor for gastroprotection.
Combining ketorolac (an NSAID) with dipyridamole (an antiplatelet) significantly increases your risk of bleeding, particularly in the stomach or intestines. This combination should generally be avoided.
Mechanism
Ketorolac inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and impairing platelet aggregation. Dipyridamole also inhibits platelet aggregation by increasing cyclic AMP levels. The concurrent use of two agents that inhibit platelet function leads to an additive antiplatelet effect.
Clinical Management
This interaction substantially increases the risk of serious bleeding events, including gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and other systemic bleeding. The risk of GI bleeding with NSAIDs alone is 2-4 times higher, and combining with antiplatelets further elevates this risk significantly. This combination should generally be avoided due to the high risk of bleeding. If concurrent therapy is absolutely necessary, use the lowest effective doses for the shortest duration possible, and monitor closely for signs of bleeding (e.g., black tarry stools, easy bruising, nosebleeds). Consider alternative pain management strategies or antiplatelet agents if appropriate.
For complete prescribing information:
View full DIPYRIDAMOLE monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.